KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on developing innovative oral therapies for individuals suffering from rare diseases with significant unmet medical needs. The company is known for its groundbreaking treatment EKTERLY®, the first and only oral on-demand therapy for hereditary angioedema (HAE). KalVista is committed to collaborating with the global HAE community to enhance treatment options and care for patients worldwide.